About RVAC Medicines

RVAC Medicines is an mRNA platform company. We are building a diverse pipeline of innovative medicines. Our leading asset, a COVID-19 vaccine, is quickly moving into clinical trials and is well-positioned to serve emerging markets in regions that are struggling with vaccine access, where we are rapidly establishing regional manufacture capabilities. Our company has built its team with top-tier scientists and established key partnerships to leverage clinically validated technologies. Incubated by the CBC Group, RVAC Medicines is headquartered in Singapore with R&D centers in Boston and Shanghai.